Significance of genetic abnormalities of p53 protein in Slovenian patients with gastric carcinoma

Croatian Medical Journal

Volumn 48, Issue 2, 2007, Pages 207-217

  Juvan, Robert ^a   Hudler, Petra ^a   Gazvoda, Barbara ^a   Repse, Stanislav ^a   Bracko, Matej ^b   Komel, Radovan ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DO 7; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENETIC DISORDER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; METASTASIS; MICROSATELLITE INSTABILITY; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SLOVENIA; STOMACH CARCINOMA;

FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; SEX DISTRIBUTION; SLOVENIA; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34247549729     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Bacani J, Zwingerman R, Di Nicola N, Spencer S, Wegrynowski T, Mitchell K, et al. Tumor microsatellite instability in early onset gastric cancer. J Mol Diagn. 2005;7:465-77.
2. Wu CW, Chi CW, Lin WC. Gastric cancer: prognostic and diagnostic advances. Expert Rev Mol Med. 2002;2002:1-12.
3. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354-62.
4. Ferlay J, Bray F, Pisani P, Parkin D. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press; 2001.
5. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
6. Tahara E, Kuniyasu H, Yasui W, Yokozaki H. Gene alterations in intestinal metaplasia and gastric cancer. Eur J Gastroenterol Hepatol. 1994;6 Suppl 1:S97-102.
7. Kountouras J, Zavos C, Chatzopoulos D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology. 2005;52:1305-12.
8. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ. 2004;(157):327-49.
9. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006;12:2979-90.
10. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12:192-8.
11. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49-95.
12. Kufe DW, Pollock RE, Wichselbaum RR, Bast RC, Gansler TS, Holland JF, et al, editors. Cancer medicine. 6th ed. Hamilton, Ontario: BC Decker; 2003.
13. Shiao YH, Palli D, Caporaso NE, Alvord WG, Amorosi A, Nesi G, et al. Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev. 2000;9:631-3.
14. Fenoglio-Preiser CM, Wang J, Stemmermann GN, Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat. 2003;21:258-70.
15. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1996;1287:77-102.
16. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13:1027-36.
17. Borrmann R. Neoplasms of Stomach and Duodenum [In German]. In: Henkie F, Lubarsch O, editors. Handbuch der Speziellen Pathologischen Anatomie und Histologie. Berlin, Springer-Verlag, 1926:865.
18. Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer. 1998;1:31-50.
19. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, et al. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis. 2002;23:419-24.
20. Cawkwell L, Lewis FA, Quirke P. Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer. 1994;70:813-8.
21. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-40.
22. Hudler P, Vouk K, Liovic M, Repse S, Juvan R, Komel R. Mutations in the hMLH1 gene in Slovenian patients with gastric carcinoma. Clin Genet. 2004;65:405-11.
23. Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol. 2005;26:65-75.
24. Zheng L, Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression. Gastric Cancer. 2004;7:61-77.
25. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006;17(suppl_7):vii97-vii102.
26. Tay ST, Leong SH, Yu K, Aggarwal A, Tan SY, Lee CH, et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Res. 2003;63:3309-16.
27. Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A, et al. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol. 2003;56:286-92.
28. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and cerbB-2 in gastric cancer. Jpn J Clin Oncol. 2003;33:173-9.
29. Muller W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J Pathol. 1996;178:255-8.
30. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol. 1999;17:1364-74.
31. Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res. 2000;6:4782-8.
32. Sul J, Yu GP, Lu QY, Lu ML, Setiawan VW, Wang MR, et al. P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions. Cancer Lett. 2006;238:210-23.
33. Soussi T, Ishioka C, Claustres M, Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer. 2006;6:83-90.
34. Sugiyama H, Arita M, Min Z, Zhong X, Iwasaki I, Hirano K, et al. A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW. Tohoku J Exp Med. 2003;201:229-37.
35. Liu XP, Tsushimi K, Tsushimi M, Oga A, Kawauchi S, Furuya T, et al. Expression of p53 protein as a prognostic indicator of reduced survival time in diffuse-type gastric carcinoma. Pathol Int. 2001;51:440-4.
36. Pinto-de-Sousa J, Silva F, David L, Leitao D, Seixas M, Pimenta A, et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology. 2004;44:323-31.